☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Hepatocellular Carcinoma (HCC)
Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) as 1L Therapy for Hepatocellular Carcin...
January 13, 2021
Exelixis' Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)
January 15, 2019
Load more...
Back to Home